Pharsight

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9517219	June, 2019	FWD Entered	Almirall, LLC	Mylan Pharmaceuticals Inc.
US9517219	November, 2018	FWD Entered	Almirall, LLC	Amneal Pharmaceuticals LLC
US9161926	February, 2018	FWD Entered	Almirall, LLC	Amneal Pharmceuticals LLC

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5863560	ALMIRALL	Compositions and methods for topical application of therapeutic agents	Sep, 2016 (7 years ago)
US6620435	ALMIRALL	Compositions for topical application of therapeutic agents	Sep, 2016 (7 years ago)
US6060085	ALMIRALL	Compositions and methods for topical application of therapeutic agents	Sep, 2016 (7 years ago)
US9517219	ALMIRALL	Topical dapsone and dapsone/adapalene compositions and methods for use thereof	Nov, 2033 (9 years from now)
US9161926	ALMIRALL	Topical dapsone and dapsone/adaplene compositions and methods for use thereof	Nov, 2033 (9 years from now)
US11273132	ALMIRALL	Topical dapsone and dapsone/adapalene compositions and methods for use thereof	Nov, 2033 (9 years from now)

Aczone is owned by Almirall.

Aczone contains Dapsone.

Aczone has a total of 6 drug patents out of which 3 drug patents have expired.

Expired drug patents of Aczone are:

Aczone was authorised for market use on 24 February, 2016.

Aczone is available in gel;topical dosage forms.

Aczone can be used as treatment of acne, topical treatment of acne vulgaris.

The generics of Aczone are possible to be released after 18 November, 2033.

Drug Exclusivity	Drug Exclusivity Expiration
New Strength(NS)	Feb 24, 2019
New Patient Population(NPP)	Sep 10, 2022

Market Authorisation Date: 24 February, 2016

Treatment: Treatment of acne; Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.075	13 Feb, 2017	1	26 Jun, 2019	18 Nov, 2033	Eligible

Strength	Dosage	Availability
7.5%	GEL;TOPICAL	Prescription

ACZONE family patents

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6060085	ABBVIE	Compositions and methods for topical application of therapeutic agents	Sep, 2016 (7 years ago)
US6620435	ABBVIE	Compositions for topical application of therapeutic agents	Sep, 2016 (7 years ago)
US5863560	ABBVIE	Compositions and methods for topical application of therapeutic agents	Sep, 2016 (7 years ago)

Aczone is owned by Abbvie.

Aczone contains Dapsone.

Aczone has a total of 3 drug patents out of which 3 drug patents have expired.

Expired drug patents of Aczone are:

Aczone was authorised for market use on 07 July, 2005.

Aczone is available in gel;topical dosage forms.

Aczone can be used as treatment of acne.

The generics of Aczone are possible to be released after 11 September, 2016.

Market Authorisation Date: 07 July, 2005

Treatment: Treatment of acne

Dosage: GEL;TOPICAL